 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| 12345678910111213...2425» |
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Erenumab in a patient with persistent headaches after subarachnoid hemorrhage: A case report of an effective treatment. (Pubmed Central) - Jan 27, 2025
To our knowledge, this is the first reported case in the literature of a patient with persistent post-subarachnoid hemorrhage headache that was successfully treated with an antibody against the CGRP receptor. This case report highlights the role of CGRP in post-subarachnoid hemorrhage headaches and the potential role for CGRP pathway-based therapies as an effective treatment.
- || PK/PD data, Review, Journal: The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review. (Pubmed Central) - Jan 3, 2025
The existence of patients with medication-resistant migraine may be due to the: (i) complex migraine pathophysiology, in which several systems appear to be deregulated before, during, and after a migraine attack; and (ii) pharmacodynamic and pharmacokinetic properties of antimigraine medications. As envisioned here, although seminal studies support the notion that CGRP plays a key role in migraine headache, the dysfunction of CGRPergic transmission does not seem to be relevant in all cases.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Switching from ligand to receptor anti-calcitonin gene-related peptide (CGRP) antibodies or vice versa in non-responders: A controlled cohort study. (Pubmed Central) - Dec 9, 2024
As envisioned here, although seminal studies support the notion that CGRP plays a key role in migraine headache, the dysfunction of CGRPergic transmission does not seem to be relevant in all cases. Transitioning to a different anti-calcitonin gene-related peptide monoclonal class yields reduction in monthly migraine days compared to returning to standard care for patients with inadequate initial treatment response.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal: Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience. (Pubmed Central) - Dec 3, 2024
Transitioning to a different anti-calcitonin gene-related peptide monoclonal class yields reduction in monthly migraine days compared to returning to standard care for patients with inadequate initial treatment response. In this difficult-to-treat patient cohort we reconfirmed the effectiveness of erenumab, but could not detect any additional benefit for a dosage escalation from 70
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world effectiveness, Real-world: Anti?CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two (Pubmed Central) - Nov 19, 2024
Anti-CGRP mAbs prove effectiveness and safety over a 24-month period in a RM population. Patients with no medication overuse and lower basal MMDs and MAM may respond better to anti-CGRP mAbs.
- || Qulipta (atogepant) / AbbVie
Review, Journal, Benefit-risk assessment: Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies. (Pubmed Central) - Nov 19, 2024
Patients with no medication overuse and lower basal MMDs and MAM may respond better to anti-CGRP mAbs. Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable (not statistically significant) with those of CGRP mAbs across all analyses.
- | Aimovig (erenumab-aooe) / Amgen, Novartis, Nurtec ODT (rimegepant ODT) / Pfizer
Journal: Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society. (Pubmed Central) - Nov 18, 2024
Availability of headache medications, ranging from simple analgesics to novel therapies migraine-specific drugs, varied greatly across the world. Actions are needed to improve effective drug availability in many countries to ensure an adequate management of people living with headache.
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) - Nov 18, 2024
P3, N=284, Active, not recruiting, Sponsor: Amgen
Actions are needed to improve effective drug availability in many countries to ensure an adequate management of people living with headache. Recruiting --> Active, not recruiting
- ||| Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Adverse events: Crowdsourcing Adverse Events Associated With Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide Signaling for Migraine Prevention: Natural Language Processing Analysis of Social Media. (Pubmed Central) - Nov 15, 2024
However, notable flagged words for erenumab included "constipation," "depression," and "vomiting." In conclusion, computational linguistics applied to social media may help identify potential adverse events for novel therapeutics. While social media data show promise for pharmacovigilance, further work is needed to improve its reliability and usability.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life. (Pubmed Central) - Nov 13, 2024
Our study highlighted more pronounced psychopathological comorbidities in patients in treatment with NON-SPECIFIC therapies in terms of impulsivity, alexithymia, and emotion regulation. Moreover, treatment efficacy overtime was more pronounced and stable over time in the SPECIFIC group, and psychopathological comorbidity did not influence it.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, HEOR: Erenumab versus topiramate: migraine-related disability, impact and health-related quality of life. (Pubmed Central) - Nov 13, 2024
Moreover, treatment efficacy overtime was more pronounced and stable over time in the SPECIFIC group, and psychopathological comorbidity did not influence it. This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient-reported outcomes versus patients treated with topiramate.
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Nov 12, 2024
P3, N=456, Recruiting, Sponsor: Amgen
This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient-reported outcomes versus patients treated with topiramate. Trial completion date: Jun 2027 --> Feb 2027
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Budget Impact of Intravenous Eptinezumab in the Prevention of Chronic Migraine Patients in United Arab Emirates () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2616;
Eptinezumab resulted in cost savings in non-drug medical expenses due to reduced frequency of migraine attacks, fewer adverse events, and lower productivity loss. Despite the upfront drug costs of eptinezumab, these were offset by the savings from reduced migraine management and productivity loss.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Price Sensitivity and Uptake of Pharmaceuticals in Sweden and Finland: The Example of New Migraine Drugs () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1058;
Included CGRP-inhibitors, reimbursed in both countries in 2020, were: Aimovig, Ajovy and Emgality. Studied price differences of CGRP-inhibitors were not large enough to influence physicians
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) - Oct 31, 2024
P3, N=286, Recruiting, Sponsor: Amgen
Studied price differences of CGRP-inhibitors were not large enough to influence physicians Trial completion date: May 2025 --> Jan 2026
- | Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Retrospective data, Journal: Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. (Pubmed Central) - Oct 29, 2024
Trial completion date: May 2025 --> Jan 2026 Eptinezumab may be an effective and well-tolerated option for some treatment-refractory migraine patients unresponsive to subcutaneous CGRP-(R) mAbs.
- || Cosentyx (secukinumab) / Novartis, Rituxan (rituximab) / Roche, Aimovig (erenumab-aooe) / Amgen, Novartis
Review, Journal: Pyoderma Gangrenosum Associated With Iatrogenic Interleukin 17A Blockade: A Report of Two Cases and (Pubmed Central) - Oct 27, 2024
More recently, certain medications were implicated, including TNF-alpha inhibitors, rituximab, and IL-17A inhibitors, such as secukinumab, where the development of PG is held to represent a cutaneous immune adverse effect...One patient received the anti-calcitonin gene-related peptide targeted therapy, erenumab, for migraine prophylaxis...We documented a microenvironment enriched in IL-17A, emphasizing that the blockade impacts the functionality of the receptor as opposed to a quantitative reduction in IL-17A production by T cells. Qualitative functional IL-17A blockade could result in a paradoxical increase in IL-23, a pro-inflammatory cytokine that may contribute to the influx of neutrophils pathogenetically implicated in PG.
- | Journal: Hypersensitivity to the CGRP Inhibitor Monoclonal Antibodies Galcanezumab, Erenumab, and Fremanezumab With Tolerance to Eptinezumab. (Pubmed Central) - Oct 23, 2024
Qualitative functional IL-17A blockade could result in a paradoxical increase in IL-23, a pro-inflammatory cytokine that may contribute to the influx of neutrophils pathogenetically implicated in PG. No abstract available
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study. (Pubmed Central) - Oct 21, 2024
No abstract available Most patients with migraine were prescribed erenumab 70
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ? 65 Years With Daily or Nondaily Migraine. (Pubmed Central) - Oct 14, 2024
This retrospective analysis provides real-world evidence that there is no difference in the efficacy and tolerability of treatment with erenumab, fremanezumab, and galcanezumab in patients O65 when compared with patients U65 both with daily or nondaily migraine. These data may help guide the choice of migraine treatment in older populations.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study. (Pubmed Central) - Oct 12, 2024
The study concludes that treatment with anti-CGRP mAbs over one year does not significantly affect BP in patients aged???60, nor does it increase the incidence of hypertension compared to general population trends. Nonetheless, continuous monitoring and further long-term studies are necessary to fullya scertain the cardiovascular safety of these medications in the elderly.
- || Clinical, Review, Journal: Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. (Pubmed Central) - Oct 4, 2024
The adverse events review included 40 randomised controlled trials with 25,891 participants; 3 additional drugs, amitriptyline, atogepant and rimegepant, were included...Consensus was reached on the top three recommendations for future research on medications to prevent chronic migraine: (1) calcitonin gene-related peptide monoclonal antibodies and Botox versus calcitonin gene-related peptide monoclonal antibodies, (2) candesartan versus placebo and (3) flunarizine versus placebo...63. See the NIHR Funding and Awards website for further award information.
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) - Sep 20, 2024
P3, N=286, Recruiting, Sponsor: Amgen
See the NIHR Funding and Awards website for further award information. Trial completion date: Apr 2027 --> May 2025 | Trial primary completion date: Apr 2026 --> Feb 2025
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH (clinicaltrials.gov) - Sep 19, 2024
P2, N=112, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Apr 2027 --> May 2025 | Trial primary completion date: Apr 2026 --> Feb 2025 Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Sep 19, 2024
P3, N=456, Recruiting, Sponsor: Amgen
Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Jun 2026 --> Jun 2027
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine. (Pubmed Central) - Sep 13, 2024
Finally, the tolerability profile for anti-CGRP mAbs was favorable. Further studies are needed to identify predictors of response after switching from the first anti-CGRP mAb treatment.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal: Changes in use of acute and preventive medications for migraine after erenumab initiation over 12?months: A United States retrospective cohort study. (Pubmed Central) - Sep 9, 2024
Further studies are needed to identify predictors of response after switching from the first anti-CGRP mAb treatment. In this long-term study, we observed the discontinuation of both acute and preventive medications for migraine post-erenumab initiation.
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Sep 4, 2024
P3, N=456, Recruiting, Sponsor: Amgen
In this long-term study, we observed the discontinuation of both acute and preventive medications for migraine post-erenumab initiation. Trial completion date: May 2027 --> Jun 2026
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 (Pubmed Central) - Aug 23, 2024
Most patients initiating erenumab had prior use of acute and traditional migraine-preventive therapies. The reduction in acute and traditional migraine-preventive medication use and HRU over the 12-month follow-up supports the long-term clinical benefits of erenumab in the real-world setting.
- | Journal, Machine learning: Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features. (Pubmed Central) - Aug 23, 2024
We demonstrated that migraine characteristics are important in predicting treatment responses and identified the most crucial predictors for each of the seven types of preventive medications. Our results suggest that precision migraine treatment is feasible.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Impact of Erenumab on Migraine Disability: A Three-Month MIDAS (Migraine Disability Assessment Scale) Score Analysis at Dubai Health Facilities. (Pubmed Central) - Aug 19, 2024
While not statistically significant due to the limited sample size and the absence of a control group, these findings suggest a potential benefit of erenumab in reducing migraine disability. Future research with more extensive, controlled trials is warranted to definitively assess erenumab's effectiveness and explore potential treatment regimen variations for optimal patient outcomes.
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment change: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) - Aug 9, 2024
P2, N=39, Completed, Sponsor: Indiana University
Future research with more extensive, controlled trials is warranted to definitively assess erenumab's effectiveness and explore potential treatment regimen variations for optimal patient outcomes. N=30 --> 39
- ||| P3 data, Retrospective data, Review, Journal: The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial. (Pubmed Central) - Aug 7, 2024
Interestingly, this analysis can be interpreted as that anti-CGRP antibodies might not be effective in reducing simple analgesics use in EM or CM patients. Further studies are needed to investigate these matters.
- Aimovig (erenumab-aooe) / Amgen, Novartis
Inhibition of the calcitonin gene-related pathway in treating rosacea-associated flushing and erythema (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4257;
Erenumab demonstrated efficacy in reducing rosacea-associated erythema and flushing, with participants generally tolerating the treatment well. This suggests that CGRP-receptor antagonism holds promise in rosacea management.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Utilisation, expenditure, and treatment patterns associated with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) reimbursed subject to a managed access protocol in Ireland. (Pubmed Central) - Aug 4, 2024
This study demonstrates the importance of active health technology management, after reimbursement, in enabling cost-effective use of high-cost treatments while providing budget certainty for the healthcare payer. High levels of adherence and persistence suggest that treatment is successfully targeted in situations which unmet clinical need is greatest.
- Aimovig (erenumab-aooe) / Amgen, Novartis
MEDICATION USE EVALUATION OF ERENUMAB (AIMOVIG) A CGRP MONOCLONAL ANTIBODY FOR MIGRAINE PROPHYLAXIS (Exhibit Hall) - Jul 31, 2024 - Abstract #PAINWeek2024PAINWeek_196;
Patients ranged in age from 27-63 in the episodic group and 27-72 in the chronic group. The average age was 48 and 51 respectively.
- |||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Real-world evidence, Real-world: Migraine Survey in Gulf Region (clinicaltrials.gov) - Jul 30, 2024
P=N/A, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
The average age was 48 and 51 respectively. Not yet recruiting --> Recruiting
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion, Enrollment change: Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial (clinicaltrials.gov) - Jul 28, 2024
P=N/A, N=48, Completed, Sponsor: Universidad de Zaragoza
Not yet recruiting --> Recruiting Recruiting --> Completed | N=182 --> 48
- || Retrospective data, Review, Journal: A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine. (Pubmed Central) - Jul 18, 2024
Four mAbs, namely, erenumab, fremanezumab, galcanezumab, and eptinezumab, have been marketed, although head-to-head trials with standard anti-migraine treatments are absent...The two studies of topiramate showed contradictory results, the one significant while the other not, with NNTs 2 and 22, respectively. All four anti-CGRP mAbs showed an invariably high efficacy among their studies, in terms of the ARD and its derivative measure of NNT, in contrast to oBTA, while in topiramate, the results are contradictory between the two studies.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study. (Pubmed Central) - Jul 16, 2024
All four anti-CGRP mAbs showed an invariably high efficacy among their studies, in terms of the ARD and its derivative measure of NNT, in contrast to oBTA, while in topiramate, the results are contradictory between the two studies. Our data showed that anti-CGRP mAbs are effective and have a rapid onset of action in CM regardless of disease duration.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Analysis to retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data. (Pubmed Central) - Jul 11, 2024
Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data. (Pubmed Central) - Jul 11, 2024
Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A-real-world data from a preliminary cohort study. (Pubmed Central) - Jul 11, 2024
It is hypothesized that the observed additive effects are due to the independent modes of action of erenumab and onabotulinumtoxin A. This study suggests that the combination of erenumab with onaBoNT-A may offer an improved approach for the treatment of chronic migraine in selected patients. However, the results highlight the need for prospective, controlled studies to validate these findings and determine the optimal combination of treatments tailored to the individual patient.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, HEOR: The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics. (Pubmed Central) - Jul 9, 2024
For more than half the patients using fremanezumab or erenumab after 3-month period, MMD decreased by ?50% and total MIDAS score by >50 points. All areas of quality of life were improved after prophylactic treatment of migraine.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Efficacy and safety of erenumab in migraine treatment. (Pubmed Central) - Jun 25, 2024
All areas of quality of life were improved after prophylactic treatment of migraine. No abstract available
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Nurtec ODT (rimegepant ODT) / Pfizer
Combined use of rimegepant and eptinezumab for treatment of chronic migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_420;
The co-administration of gepants and CGRP targeted mAbs can be effective in reducing severity and frequency of chronic migraine headaches. Patient did not report any adverse side effects from the combined use of these medications.
- Which combination of comorbidity makes migraine treatment impossible? A graphical approach () - Jun 18, 2024 - Abstract #AHS2024AHS_411;
Despite the diverse comorbidities considered, no combination of abortive or prevention medications was found to be entirely contraindicated for migraine patients. However, cardiac comorbidities such as uncontrolled hypertension or hypotension, prior coronary artery disease, and heart failure could significantly limit the possibility of abortive and preventive treatments.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
The impact and management of "wearing-off" in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_402;
However, physicians perceive less wearing-off with fremanezumab compared with other CGRP pathway mAbs and manage wearing-off with lifestyle or treatment changes. Further research is needed to see if these strategies for managing wearing-off can effectively address patients' symptoms and work to mitigate at least some HCRU.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Real-world evidence and economic considerations of CGRP mAbs in Thailand: A retrospective analysis in middle-income countries () - Jun 18, 2024 - Abstract #AHS2024AHS_386;
Nevertheless, it is noteworthy that the cost of migraine treatment increased substantially after the initiation of CGRP mAbs, despite remaining stable thereafter. Further investigation into direct or indirect cost-utility analysis may be warranted in LMICs.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Real-world effectiveness of intravenous eptinezumab in patients with chronic migraine and previous subcutaneous preventive migraine treatment () - Jun 18, 2024 - Abstract #AHS2024AHS_385;
All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). This real-world patient survey study demonstrated that individuals with prior exposure to subcutaneous anti-CGRP monoclonal antibodies expressed high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.